Lupin Secures Tentative U.S. Approval for Its Multiple Sclerosis Tablet
Lupin has received tentative U.S. FDA approval for its oral multiple-sclerosis treatment, reinforcing its growing footprint in complex generic neurology products. The approval allows Lupin to market the drug upon the resolution of originator patent or exclusivity barriers, positioning it for rapid entry once regulatory windows open. The product strengthens Lupin’s specialty generics strategy and enhances its exposure to the high-value central nervous system market, where competition is limited and pricing remains resilient. Industry observers see this as a strategic upgrade from volume-driven generics toward margin-protected complex therapies.
You May Interested In
High Quality β-Nicotinamide adenine dinucleotide CAS 53-84-9 NADwith ready stock and best price
$3/UNIT FOB
2026-10-10
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Lotte Chemical Jumps Nearly 13% as Korean Petrochemical Stocks Rally on Supply-Tightening Bets
-
Ammonia Leaks in Iraq and Jordan Put Fertilizer Production and Port Safety on Alert
-
ExxonMobil’s 264,000-bpd Joliet Refinery Shuts After Site-Wide Power Failure
-
Huide Technology Partners with U.S. Firm to Open the Door to Mass Production of Circular TPU
-
LG Chem Teams Up with Jianghua Microelectronics to Advance Semiconductor Ultra-High-Purity IPA
-
From Eggshell to Elixir: EFSA Declares Egg Membrane Collagen Peptides Safe for Adult Supplements
-
Sika in China Under Pressure: The Structural Alarm Behind the 1,500-Job Cut
-
Blue from the Rainforest: EFSA Greenlights Natural “Jagua Blue” as Safe Food Colorant
-
From Ancient Volcanoes to Modern Feed Mills: EFSA Validates Volcanic Zeolite as Safe and Effective Feed Additive
-
Probiotic Promise, Safety Snag: EFSA Gives Mixed Verdict on Multi-Strain Dog Feed Additive
Recommend Reading
-
![Bridgestone Reports Q3 Growth Amid Challenging North American Market]()
Bridgestone Reports Q3 Growth Amid Challenging North American Market
-
![Chung Lien Oil’s 8,000-Ton Soybean Oil BaP Scandal: NT$165 Million Fine, 401 Product Recalls, Source Still Unknown]()
Chung Lien Oil’s 8,000-Ton Soybean Oil BaP Scandal: NT$165 Million Fine, 401 Product Recalls, Source Still Unknown
-
![Brazil Expands Chemical Tax Breaks as India’s Crop Protection Industry Warns of a 25% Cost Increase]()
Brazil Expands Chemical Tax Breaks as India’s Crop Protection Industry Warns of a 25% Cost Increase
-
![25 Companies Raise Prices Three Times Within a Month: China’s Titanium Dioxide Industry Shifts from “Price Wars” to a “Pricing Alliance”]()
25 Companies Raise Prices Three Times Within a Month: China’s Titanium Dioxide Industry Shifts from “Price Wars” to a “Pricing Alliance”
-
![High Crude Prices Are Passing Through the Coatings Chain as More Than 20 Companies Launch Price Increases]()
High Crude Prices Are Passing Through the Coatings Chain as More Than 20 Companies Launch Price Increases
-
![Business Society’s Melamine Trend Analysis on September 15, 2026: Downward Trend]()
Business Society’s Melamine Trend Analysis on September 15, 2026: Downward Trend
-
![This Week, the Transaction Focus of China's Propylene Oxide Market Rises (11.10-11.14)]()
This Week, the Transaction Focus of China's Propylene Oxide Market Rises (11.10-11.14)
-
![Business Society’s PET Trend Analysis for September 15, 2026: Anti-Depreciation Early Warning]()
Business Society’s PET Trend Analysis for September 15, 2026: Anti-Depreciation Early Warning
-
![Business Society September 15, 2026 Ethyl Acetate Trend Analysis: Volatile]()
Business Society September 15, 2026 Ethyl Acetate Trend Analysis: Volatile
-
![Business Society’s September 14, 2026, Petroleum Coke Trend Analysis: Volatile]()
Business Society’s September 14, 2026, Petroleum Coke Trend Analysis: Volatile
